ADCT — Adc Therapeutics Share News
0.000.00%
Last trade - 00:00- $190.22m
- $387.28m
- $81.36m
ADC Therapeutics SA reports results for the quarter ended in March - Earnings Summary
ADC Therapeutics SA expected to post a loss of 70 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 70 cents a share - Earnings Preview
ADC Therapeutics SA reports results for the quarter ended in December - Earnings Summary
Brief: Adc Therapeutics Q4 Cash And Cash Equivalents Were $466.5 Mln
ADC Therapeutics SA expected to post a loss of 86 cents a share - Earnings Preview
Brief: Adc Therapeutics Says Announced Exclusive License With Mitsubishi Tanabe Pharma Corporation To Develop And Commercialize Zynlonta® In Japan
ADC Therapeutics SA reports results for the quarter ended in September - Earnings Summary
Brief: ADC Therapeutics SA Q3 Sales $13.1 Mln
ADC Therapeutics SA expected to post a loss of 92 cents a share - Earnings Preview
Brief: ADC Therapeutics Doses First Patient In Phase 1 Clinical Trial Of ADCT-901 In Advanced Solid Tumors
U.S. RESEARCH ROUNDUP-CF Industries Holdings, DXC Technology Co, Rackspace Technology
ADC Therapeutics rises as newly approved cancer drug brings in nearly $4 mln in sales
ADC Therapeutics SA reports results for the quarter ended in June - Earnings Summary
ADC Therapeutics SA expected to post a loss of 86 cents a share - Earnings Preview
NYSE ORDER IMBALANCE 295627.0 SHARES ON BUY SIDE
Brief: ADC Therapeutics Announces Encouraging Interim Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine Presented At The 16Th Annual International Conference On Malignant Lymphoma
Brief: ADC Therapeutics SA Files For Shelf Of Up To 5.6 Mln Shares
ADC Therapeutics SA reports results for the quarter ended in March - Earnings Summary